Atsutaka Yasui

5PUBLICATIONS
14CO-AUTHORS
Epidemiological modellingNutritional epidemiologyMajor global burdens of diseaseSocial epidemiologyElectrochemical energy storage and conversion
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 30, 2023
Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.

Dae Jung Kim, Wayne H-H Sheu, Wook-Jin Chung

|Mar 22, 2022
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.

Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima

|Dec 15, 2021
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.

Kohei Kaku, Christoph Wanner, Stefan D Anker

|Feb 03, 2021
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.

Yutaka Seino, Dae Jung Kim, Daisuke Yabe

|Oct 02, 2020
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.

Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik

Pageof 1

Frequent Collaborators

2 joint publications

Dae Jung Kim

2 joint publications

Koichi Node

2 joint publications

Wayne H-H Sheu

2 joint publications

Kohei Kaku